Human natural killer cells: Origin, receptors, function, and clinical applications

International Archives of Allergy and Immunology

Volumn 164, Issue 4, 2014, Pages 253-264

  Moretta, Lorenzo ^a   Montaldo, Elisa ^a   Vacca, Paola ^a   Del Zotto, Genny ^a   Moretta, Francesca ^c   Merli, Pietro ^c   Locatelli, Franco ^c   Mingari, Maria Cristina ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Activating NK receptors; Haploidentical hematopoietic stem cell transplantation; Killer Ig like receptors; Natural killer cells; NK tumor cell interactions

Indexed keywords

CD16 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; CELL RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; SIGNAL PEPTIDE; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR; HLA ANTIGEN;

ALLOIMMUNITY; CANCER RECURRENCE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CELL INTERACTION; CELL MATURATION; CELL POPULATION; CYTOKINE PRODUCTION; GENE FREQUENCY; GENETIC CODE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LEUKEMIA; LEUKEMIA RELAPSE; NATURAL KILLER CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SEQUENCE HOMOLOGY; SOLID TUMOR; T CELL DEPLETION; IMMUNOLOGY; INNATE IMMUNITY; NEOPLASM; VIRUS INFECTION;

HLA ANTIGENS; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LEUKEMIA; NEOPLASMS; VIRUS DISEASES;

EID: 84908566276     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000365632     Document Type: Review

References (123)

1. Herberman RB, Nunn ME, Lavrin DH: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors.I. Distribution of reactivity and specificity. Int J Cancer 1975; 16: 216-229.
2. Herberman RB, Nunn ME, Holden HT, Lavrin DH: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975; 16: 230-239.
3. Kiessling R, Klein E, Wigzell H: Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5: 112-117.
4. Kiessling R, Klein E, Pross H, Wigzell H: Natural' killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975; 5: 117-121.
5. Shi FD, Ljunggren HG, La Cava A, Van Kaer L: Organ-specific features of natural killer cells. Nat Rev Immunol 2011; 11: 658-671.
6. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-49.
7. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L: Receptors for HLA class I molecules in human natural killer cells. Annu Rev Immunol 1996; 14: 619-648.
8. Yokoyama WM, Seaman WE: The LY-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex. Annu Rev Immunol 1993; 11: 613-635.
9. Karre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-678.
10. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L: Activating receptors and co-receptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19: 197-223.
11. Walker JA, Barlow JL, McKenzie AN: Innate lymphoid cells-how did we miss them? Nat Rev Immunol 2013; 13: 75-87.
12. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, Moretta L: Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A 2013; 83: 702-713.
13. Yu J, Freud AG, Caligiuri MA: Location and cellular stages of natural killer cell development. Trends Immunol 2013; 34: 573-582.
14. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A: Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113: 3119-3129.
15. Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, Nishikawa S, Gruss P: Development of peripheral lymphoid organs and natural killer cells depends on the helixloop-helix inhibitor ID2. Nature 1999; 397: 702-706.
16. Boos MD, Yokota Y, Eberl G, Kee BL: Mature natural killer cell and lymphoid tissue-inducing cell development requires ID2-mediated suppression of E protein activity. J Exp Med 2007; 204: 1119-1130.
17. Colucci F, Samson SI, DeKoter RP, Lantz O, Singh H, Di Santo JP: Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood 2001; 97: 2625-2632.
18. Barton K, Muthusamy N, Fischer C, Ting CN, Walunas TL, Lanier LL, Leiden JM: The ETS-1 transcription factor is required for the development of natural killer cells in mice. Immunity 1998; 9: 555-563.
19. Aliahmad P, de la Torre B, Kaye J: Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat Immunol 2010; 11: 945-952.
20. Yun S, Lee SH, Yoon SR, Kim MS, Piao ZH, Myung PK, Kim TD, Jung H, Choi I: TOX regulates the differentiation of human natural killer cells from hematopoietic stem cells in vitro. Immunol Lett 2011; 136: 29-36.
21. Gascoyne DM, Long E, Veiga-Fernandes H, de Boer J, Williams O, Seddon B, Coles M, Kioussis D, Brady HJ: The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 2009; 10: 1118-1124.
22. Kamizono S, Duncan GS, Seidel MG, Morimoto A, Hamada K, Grosveld G, Akashi K, Lind EF, Haight JP, Ohashi PS, Look AT, Mak TW: NFIL3/E4BP4 is required for the development and maturation of NK cells in vivo. J Exp Med 2009; 206: 2977-2986.
23. Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, Lindsten T, Reiner SL: The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012; 36: 55-67.
24. Freud AG, Caligiuri MA: Human natural killer cell development. Immunol Rev 2006; 214: 56-72.
25. Minagawa M, Watanabe H, Miyaji C, Tomiyama K, Shimura H, Ito A, Ito M, Domen J, Weissman IL, Kawai K: Enforced expression of BCL-2 restores the number of NK cells, but does not rescue the impaired development of NKT cells or intraepithelial lymphocytes, in IL-2/IL-15 receptor β-chaindeficient mice. J Immunol 2002; 169: 4153-4160.
26. Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA: Flt3 ligand promotes the generation of a distinct CD34 + human natural killer cell progenitor that responds to interleukin-15. Blood 1998; 92: 3647-3657.
27. Carson WE, Haldar S, Baiocchi RA, Croce CM, Caligiuri MA: The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci USA 1994; 91: 7553-7557.
28. Sivori S, Cantoni C, Parolini S, Marcenaro E, Conte R, Moretta L, Moretta A: IL-21 induces both rapid maturation of human CD34 + cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol 2003; 33: 3439-3447.
29. Montaldo E, Vitale C, Cottalasso F, Conte R, Glatzer T, Ambrosini P, Moretta L, Mingari MC: Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor. Blood 2012; 119: 3987-3996.
30. Montaldo E, Vacca P, Moretta L, Mingari MC: Understanding human NK cell differentiation: clues for improving the haploidentical hematopoietic stem cell transplantation. Immunol Lett 2013; 155: 2-5.
31. Montaldo E, Vacca P, Moretta L, Mingari MC: Development of human natural killer cells and other innate lymphoid cells. Semin Immunol 2014; 26: 107-113.
32. Di Santo JP: Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006; 24: 257-286.
33. Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, Nuovo GJ, Hughes TL, Marburger TB, Sung J, Baiocchi RA, Guimond M, Caligiuri MA: A human CD34 + subset resides in lymph nodes and differentiates into CD56 bright natural killer cells. Immunity 2005
34. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, Ferketich AK, Caligiuri MA: Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006; 203: 1033-1043.
35. Mingari MC, Poggi A, Biassoni R, Bellomo R, Ciccone E, Pella N, Morelli L, Verdiani S, Moretta A, Moretta L: In vitro proliferation and cloning of CD3-CD16 + cells from human thymocyte precursors. J Exp Med 1991; 174: 21-26.
36. Moroso V, Famili F, Papazian N, Cupedo T, van der Laan LJ, Kazemier G, Metselaar HJ, Kwekkeboom J: NK cells can generate from precursors in the adult human liver. Eur J Immunol 2011; 41: 3340-3350.
37. Vacca P, Vitale C, Montaldo E, Conte R, Cantoni C, Fulcheri E, Darretta V, Moretta L, Mingari MC: CD34 + hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci USA 2011; 108: 2402-2407.
38. Chinen H, Matsuoka K, Sato T, Kamada N, Okamoto S, Hisamatsu T, Kobayashi T, Hasegawa H, Sugita A, Kinjo F, Fujita J, Hibi T: Lamina propria c-kit + immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 2007; 133: 559-573.
39. Male V, Hughes T, McClory S, Colucci F, Caligiuri MA, Moffett A: Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. J Immunol 2010; 185: 3913-3918.
40. Poggi A, Sargiacomo M, Biassoni R, Pella N, Sivori S, Revello V, Costa P, Valtieri M, Russo G, Mingari MC, et al: Extrathymic differentiation of T lymphocytes and natural killer cells from human embryonic liver precursors. Proc Natl Acad Sci USA 1993; 90: 4465-4469.
41. Mebius RE, Miyamoto T, Christensen J, Domen J, Cupedo T, Weissman IL, Akashi K: The fetal liver counterpart of adult common lymphoid progenitors gives rise to all lymphoid lineages, CD45 + CD4 + CD3-cells, as well as macrophages. J Immunol 2001; 166: 6593-6601.
42. Vargas CL, Poursine-Laurent J, Yang L, Yokoyama WM: Development of thymic NK cells from double negative 1 thymocyte precursors. Blood 2011; 118: 3570-3578.
43. Erlebacher A: Immunology of the maternalfetal interface. Annu Rev Immunol 2013; 31: 387-411.
44. Della Chiesa M, Falco M, Podesta M, Locatelli F, Moretta L, Frassoni F, Moretta A: Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood 2012; 119: 399-410.
45. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, Parolini S, Moretta L, Moretta A, Biassoni R: NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999; 189: 787-796.
46. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R, Bottino C, Moretta L, Moretta A: Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999; 190: 1505-1516.
47. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, Moretta L, Moretta A: p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997; 186: 1129-1136.
48. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A: NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998; 187: 2065-2072.
49. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, Phillips JH: DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996; 4: 573-581.
50. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A: Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198: 557-567.
51. Lanier LL: Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495-502.
52. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH: An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730-732.
53. Nakajima H, Cella M, Langen H, Friedlein A, Colonna M: Activating interactions in human NK cell recognition: the role of 2B4CD48. Eur J Immunol 1999; 29: 1676-1683.
54. Perussia B, Starr S, Abraham S, Fanning V, Trinchieri G: Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol 1983; 130: 2133-2141.
55. Perussia B, Acuto O, Terhorst C, Faust J, Lazarus R, Fanning V, Trinchieri G: Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. II. Studies of B73.1 antibody-antigen interaction on the lymphocyte membrane. J Immunol 1983; 130: 2142-2148.
56. Lopez-Botet M, Perez-Villar JJ, Carretero M, Rodriguez A, Melero I, Bellon T, Llano M, Navarro F: Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. Immunol Rev 1997; 155: 165-174.
57. Moretta A, Bottino C, Pende D, Tripodi G, Tambussi G, Viale O, Orengo A, Barbaresi M, Merli A, Ciccone E, et al: Identification of four subsets of human CD3-CD16 + natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990; 172: 1589-1598.
58. Moretta A, Tambussi G, Bottino C, Tripodi G, Merli A, Ciccone E, Pantaleo G, Moretta L: A novel surface antigen expressed by a subset of human CD3-CD16 + natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med 1990; 171: 695-714.
59. Ciccone E, Pende D, Viale O, Di Donato C, Tripodi G, Orengo AM, Guardiola J, Moretta A, Moretta L: Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 1992; 175: 709-718.
60. Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, Barbaresi M, Ciccone E, Moretta L: P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 1993; 178: 597-604.
61. Olcese L, Lang P, Vely F, Cambiaggi A, Marguet D, Blery M, Hippen KL, Biassoni R, Moretta A, Moretta L, Cambier JC, Vivier E: Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases. J Immunol 1996; 156: 4531-4534.
62. Moretta L, Moretta A: Killer immunoglobulin-like receptors. Curr Opin Immunol 2004; 16: 626-633.
63. Parham P: MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5: 201-214.
64. Parham P, Moffett A: Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013; 13: 133-144.
65. Falco M, Moretta L, Moretta A, Bottino C: KIR and KIR ligand polymorphism: a new area for clinical applications? Tissue Antigens 2013; 82: 363-373.
66. Sivori S, Falco M, Carlomagno S, Romeo E, Soldani C, Bensussan A, Viola A, Moretta L, Moretta A: A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood 2010; 116: 1637-1647.
67. Sivori S, Carlomagno S, Pesce S, Moretta A, Vitale M, Marcenaro E: TLR/NCR/KIR: which one to use and when? Front Immunol 2014; 5: 105.
68. Sivori S, Carlomagno S, Falco M, Romeo E, Moretta L, Moretta A: Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 2011; 117: 4284-4292.
69. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B: KIR2DS1-positive NK cells mediate alloresponse against the C2 HLAKIR ligand group in vitro. J Immunol 2007; 179: 854-868.
70. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A: Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011; 117: 764-771.
71. Caligiuri MA: Human natural killer cells. Blood 2008; 112: 461-469.
72. Bryceson YT, March ME, Ljunggren HG, Long EO: Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006; 214: 73-91.
73. De Maria A, Bozzano F, Cantoni C, Moretta L: Revisiting human natural killer cell subset function revealed cytolytic CD56 dtm CD16 + NK cells as rapid producers of abundant IFN-γ on activation. Proc Natl Acad Sci USA 2011; 108: 728-732.
74. Bryceson YT, March ME, Ljunggren HG, Long EO: Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006; 107: 159-166.
75. Fauriat C, Long EO, Ljunggren HG, Bryceson YT: Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010; 115: 2167-2176.
76. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J: Functional consequences of interleukin-2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high-affinity receptors. J Exp Med 1990; 171: 1509-1526.
77. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Munz C: The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004; 172: 1455-1462.
78. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA: CD56 bright natural killer cells are present in human lymph nodes and are activated by Tcell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101: 3052-3057.
79. Romagnani C, Juelke K, Falco M, Morandi B, D'Agostino A, Costa R, Ratto G, Forte G, Carrega P, Lui G, Conte R, Strowig T, Moretta A, Munz C, Thiel A, Moretta L, Ferlazzo G: CD56 bright CD16-killer Ig-like receptor NK cells display longer telomeres and acquire features of CD56 dtm NK cells upon activation. J Immunol 2007; 178: 4947-4955.
80. Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B, Ferlazzo G, Thiel A, Schmitt-Knosalla I, Romagnani C: CD62L expression identifies a unique subset of polyfunctional CD56 dtm NK cells. Blood 2010; 116: 1299-1307.
81. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, Corcuff E, Mortier E, Jacques Y, Spits H, Di Santo JP: IL-15 transpresentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009; 206: 25-34.
82. Moretta L: Dissecting CD56 dtm human NK cells. Blood 2010; 116: 3689-3691.
83. Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Bjorklund AT, Flodstrom-Tullberg M, Michaelsson J, Rottenberg ME, Guzman CA, Ljunggren HG, Malmberg KJ: Expression patterns of NKG2A, KIR, and CD57 define a process of CD56 dtm NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116: 3853-3864.
84. Moretta L, Pietra G, Montaldo E, Vacca P, Pende D, Falco M, Del Zotto G, Locatelli F, Moretta A, Mingari MC: Human NK cells: From surface receptors to the therapy of leukemias and solid tumors. Front Immunol 2014; 5: 87.
85. Pietra G, Manzini C, Vitale M, Balsamo M, Ognio E, Boitano M, Queirolo P, Moretta L, Mingari MC: Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 2009; 21: 793-801.
86. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, Bottino C: NK cells recognize and kill human glioblastoma cells with stem celllike properties. J Immunol 2009; 182: 3530-3539.
87. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356: 1795-1799.
88. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997; 79: 2320-2328.
89. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T: Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88: 577-583.
90. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M, Callol L: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35: 23-28.
91. Sutlu T, Alici E: Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009; 266: 154-181.
92. Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, Moch H, Terracciano L, Tornillo L: Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves β 2-integrin-mediated interaction. Neoplasia 2009; 11: 662-671.
93. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, Andre P, Romagne F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D: Human breast cancer cells enhance self-tolerance by promoting evasion from NK cell anti-tumor immunity. J Clin Invest 2011; 121: 3609-3622.
94. Balsamo M, Vermi W, Parodi M, Pietra G, Manzini C, Queirolo P, Lonardi S, Augugliaro R, Moretta A, Facchetti F, Moretta L, Mingari MC, Vitale M: Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor. Eur J Immunol 2012; 42: 1833-1842.
95. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC: Melanoma cells inhibit NK cell functions. Cancer Res 2012; 72: 5428-5429; author reply 5430.
96. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G: Natural killer cells infiltrating human non-small-cell lung cancer are enriched in CD56 bright CD16-cells and display an impaired capability to kill tumor cells. Cancer 2008; 112: 863-875.
97. Le Maux Chansac B, Moretta A, Vergnon I, Opolon P, Lecluse Y, Grunenwald D, Kubin M, Soria JC, Chouaib S, Mami-Chouaib F: NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol 2005; 175: 5790-5798.
98. Groh V, Wu J, Yee C, Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738.
99. Roda-Navarro P, Vales-Gomez M, Chisholm SE, Reyburn HT: Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc Natl Acad Sci USA 2006; 103: 11258-11263.
100. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, Solari N, Gualco M, Queirolo P, Moretta L, Mingari MC: Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012; 72: 1407-1415.
101. Balsamo M, Scordamaglia F, Pietra G, Manzini C, Cantoni C, Boitano M, Queirolo P, Vermi W, Facchetti F, Moretta A, Moretta L, Mingari MC, Vitale M: Melanoma-associated fibroblasts modulate NK cell phenotype and anti-tumor cytotoxicity. Proc Natl Acad Sci USA 2009; 106: 20847-20852.
102. Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Honig A, Hausler S, Voigt H, Becker JC, Leng L, Steinle A, Weller M, Bucala R, Dietl J, Wischhusen J: Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 2008; 180: 7338-7348.
103. Balsamo M, Manzini C, Pietra G, Raggi F, Blengio F, Mingari MC, Varesio L, Moretta L, Bosco MC, Vitale M: Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. Eur J Immunol 2013; 43: 2756-2764.
104. Vacca P, Martini S, Garelli V, Passalacqua G, Moretta L, Mingari MC: NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. Eur J Immunol 2013; 43: 550-561.
105. Terme M, Fridman WH, Tartour E: NK cells from pleural effusions are potent anti-tumor effector cells. Eur J Immunol 2013; 43: 331-334.
106. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
107. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, Hodes MZ, Good RA, O'Reilly RJ: Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983; 61: 341-348.
108. Locatelli F, Merli P, Rutella S: At the bedside: Innate immunity as an immunotherapy tool for hematological malignancies. J Leukoc Biol 2013; 94: 1141-1157.
109. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C, et al: Successful engraftment of T-cell-depleted haploidentical three-loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
110. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y, Martelli MF: Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
111. Danby R, Rocha V: Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol 2014; 5: 68.
112. Tanaka J, Sugita J, Asanuma S, Arita K, Shono Y, Kikutchi M, Shiratori S, Wakasa K, Yasumoto A, Shigematu A, Kondo T, Kobayashi T, Asaka M, Imamura M: Increased number of CD16 + CD56 dtm NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation. Hum Immunol 2009; 70: 701-705.
113. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS: Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411-2419.
114. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, Falco M, Lanino E, Pierri I, Zambello R, Bacigalupo A, Mingari MC, Moretta A, Moretta L: Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the poliovirus receptor (CD155) and nectin-2 (CD112). Blood 2005; 105: 2066-2073.
115. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC: HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012; 367: 805-816.
116. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ: Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after non-myeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010; 16: 533-542.
117. Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C, Locatelli F, Aversa F, Velardi A: Survival after T-celldepleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008; 112: 2990-2995.
118. Locatelli F, Pende D, Mingari MC, Bertaina A, Falco M, Moretta A, Moretta L: Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol 2013; 4: 15.
119. Handgretinger R: New approaches to graft engineering for haploidentical bone marrow transplantation. Semin Oncol 2012; 39: 664-673.
120. Locatelli F, Moretta F, Brescia L, Merli P: Natural killer cells in the treatment of highrisk acute leukaemia. Semin Immunol 2014; 26: 173-179.
121. Norell H, Moretta A, Silva-Santos B, Moretta L: At the bench: preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias. J Leukoc Biol 2013; 94: 1123-1139.
122. Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, Pende D, Falco M, Handgretinger R, Moretta F, Lucarelli B, Brescia LP, Li Pira G, Testi M, Cancrini C, Kabbara N, Carsetti R, Finocchi A, Moretta A, Moretta L, Locatelli F: Hla-haploidentical stem cell transplantation after removal of alphabeta+ t and b cells in children with nonmalignant disorders. Blood 2014;124:822-826.
123. Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N: Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114: 2667-2677.